Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 7/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 2/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361715 | 0.97 | TLR4 (0.40) | CNR2TLR4 | |
| SCHEMBL29499924 | 0.94 | PRKCA (0.41) | PRKCA | |
| SCHEMBL30190242 | 0.94 | PRKCA (0.41) | PRKCA | |
| SCHEMBL3887099 | 0.94 | PRKCA (0.41) | PRKCA | |
| SCHEMBL3889152 | 0.94 | PRKCA (0.41) | PRKCA | |
| SCHEMBL285607 | 0.83 | PRKCA (0.43) | PRKCA | |
| SCHEMBL29362108 | 0.83 | PRKCA (0.43) | PRKCA | |
| SCHEMBL29377047 | 0.79 | CNR2 (0.39) | PRKCACNR2DGKATLR4LPAR1 | |
| SCHEMBL29456958 | 0.79 | CNR2 (0.39) | PRKCACNR2DGKATLR4LPAR1 | |
| SCHEMBL9825412 | 0.79 | TLR4 (0.45) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302753-A1 | Membrane-forming composition, membrane-like composition, and use of same | TOWA PHARMACEUTICAL CO., LTD (JP) | 2025-10-02 | — | — | US | claimed |
| EP-4527411-A1 | MEMBRANE-FORMING COMPOSITION, MEMBRANE-LIKE COMPOSITION, AND USE OF SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2025-03-26 | — | — | EP | claimed |
| EP-4707338-A1 | COMPOSITION | Daikin Industries, Ltd. (JP) | 2026-03-11 | — | — | EP | disclosed |
| EP-4696749-A1 | COMPOSITION | Daikin Industries, Ltd. (JP) | 2026-02-18 | — | — | EP | disclosed |
| EP-4640767-A1 | COMPOSITION | Daikin Industries, Ltd. (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250311756-A1 | AGENT FOR REDUCING CONTAMINATION IN FRYING OIL | J-OIL MILLS, INC. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-20250302753-A1 | Membrane-forming composition, membrane-like composition, and use of same | TOWA PHARMACEUTICAL CO., LTD (JP) | 2025-10-02 | — | — | US | disclosed |
| US-20250186960-A1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LIMITED (GB) | 2025-06-12 | — | — | US | disclosed |
| US-20250176547-A1 | AGRICULTURE COMPOSITION | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2025-06-05 | — | — | US | disclosed |
| EP-4527411-A1 | MEMBRANE-FORMING COMPOSITION, MEMBRANE-LIKE COMPOSITION, AND USE OF SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2025-03-26 | — | — | EP | disclosed |
| EP-4501137-A1 | OIL-IN-WATER TYPE EMULSION COMPOSITION AND BEVERAGE CONTAINING SAME | Mitsubishi Chemical Corporation (JP) | 2025-02-05 | — | — | EP | disclosed |
| EP-3950000-A1 | EMULSION COMPOSITION COMPRISING ULTRAVIOLET WAVELENGTH CONVERSION SUBSTANCE AND ORGANIC OILY PHASE THICKENER | Shiseido Company, Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20170367973-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2017-12-28 | — | — | US | disclosed |
| US-20160022569-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| CN-103525602-B | Soap lye | SHANGHAI SOAPMAKING CO., LTD. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-103525602-A | Soap solution | SHANGHAI SOAP CO LTD | 2014-01-22 | — | — | CN | disclosed |
| EP-2428200-A2 | Novel compositions | Malvern Cosmeceutics Limited (GB) | 2012-03-14 | — | — | EP | disclosed |
| US-20100062067-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-2099410-A2 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | Malvern Cosmeceutics Limited (GB) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008065451-A2 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170367973-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | APOB, CLTB, ABCB4 | PRKCA 3577/4885CNR2 4193/4885DGKA 1366/4885 |
| US-20250176547-A1 | AGRICULTURE COMPOSITION | FFAR1, GYS1, SCD | PRKCA 1079/4885CNR2 1515/4885DGKA 276/4885 |
| US-20160022569-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | APOB, CLTB, ABCB4 | PRKCA 3577/4885CNR2 4193/4885DGKA 1366/4885 |
| US-20250302753-A1 | Membrane-forming composition, membrane-like composition, and use of same | STOM, LIPA, MGLL | PRKCA 1889/4885CNR2 3005/4885DGKA 273/4885 |
| US-20100062067-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | CLTB, APOB, ABCB4 | PRKCA 3294/4885CNR2 3591/4885DGKA 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.